Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation
| العنوان: | Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation |
|---|---|
| المؤلفون: | Caballero JC, Sánchez Barba M, Hernández Sánchez JM, Such E, Janusz K, Sanz G, Cabrero M, Chillón C, Cervera J, Hurtado AM, Jerez A, Calderón Cabrera C, Valcárcel D, Lumbreras E, Abáigar M, López Cadenas F, Hernández Rivas JM, Del Cañizo MC, Díez Campelo M |
| المصدر: | ANNALS OF HEMATOLOGY r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname |
| بيانات النشر: | SPRINGER, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | hemic and lymphatic diseases, Allogeneic hematopoietic stem cell transplantation, Chronic graft-versus-host disease, Myelodysplastic syndromes, Somatic mutations, TP53 |
| الوصف: | Somatic mutations in patients with myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic stem cell transplantation (HSTC) are associated with adverse outcome, but the role of chronic graft-versus-host disease (cGVHD) in this subset of patients remains unknown. We analyzed bone marrow samples from 115 patients with MDS collected prior to HSCT using next-generation sequencing. Seventy-one patients (61%) had at least one mutated gene. We found that patients with a higher number of mutated genes (more than 2) had a worse outcome (2years overall survival [OS] 54.8% vs. 31.1%, p = 0.035). The only two significant variables in the multivariate analysis for OS were TET2 mutations (p = 0.046) and the development of cGVHD, considered as a time-dependent variable (p 0.001), correlated with a worse and a better outcome, respectively. TP53 mutations also demonstrated impact on the cumulative incidence of relapse (CIR) (1year CIR 47.1% vs. 9.8%, p = 0.006) and were related with complex karyotype (p = 0.003). cGVHD improved the outcome even among patients with more than 2 mutated genes (1-year OS 88.9% at 1year vs. 31.3%, p = 0.02) and patients with TP53 mutations (1-year CIR 20% vs. 42.9%, p = 0.553). These results confirm that cGVHD could ameliorate the adverse impact of somatic mutations in patients with MDS with HSCT. |
| تدمد: | 0939-5555 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::015a5ae7668728b22adad78b2800b4d0Test https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=10361Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.RECOLECTA.....015a5ae7668728b22adad78b2800b4d0 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 09395555 |
|---|